2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
The effect size is smaller than direct HGH or strong GLP-1s, but the safety profile is favorable
Biodiversity Data Journal , 2024 , 12 , e130400
Overman MJ, Bergamo F, McDermott RS, Aglietta M, Chen F, Gelsomino F, Wong M, Morse M, Van Cutsem E, Hendlisz A, Neyns B, Moss RA, Zhao H, Cao ZA, Kamble S, Kopetz S , Andre T
This is significant because safe and effective treatments for ASD remain limited
Sustained GLP-1 therapy depends on regular provider communication, consistent follow-up appointments, and willingness to adjust doses or switch medications if tolerance or efficacy concerns emerge